Cited 5 times in
Allogeneic stem cell transplantation in patients with non-Hodgkin lymphoma who experienced relapse or progression after autologous stem cell transplantation.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김진석 | - |
dc.date.accessioned | 2018-11-23T11:33:05Z | - |
dc.date.available | 2018-11-23T11:33:05Z | - |
dc.date.issued | 2011 | - |
dc.identifier.issn | 0939-5555 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/165800 | - |
dc.description.abstract | There are few treatment options for patients with non-Hodgkin lymphoma (NHL) who experienced progression after high-dose chemotherapy (HDC) with autologous stem cell transplantation (auto-SCT). The role of allogeneic stem cell transplantation (allo-SCT) in these patients has not been clarified yet. In this study, we report clinical outcomes of allo-SCT in patients with NHL who experienced progression after HDC with auto-SCT. Patients were enrolled from seven hospitals in Korea. A total of 38 patients were included: 18 patients (47.4%) underwent myeloablative conditioning and 20 patients (52.6%) reduced intensity conditioning. Overall response rate was 73.3%. Median event-free survival was 6.3 months. Median overall survival (OS) was 19.0 months. Estimated 5-year survival rate was 35.0%. Acute graft-versus-host disease developed in 13 patients (34.2%). Transplant-related mortality (TRM) was 21.1% (eight patients). Ann Arbor stage (p=0.022), performance status (p<0.001), and baseline serum albumin level (p=0.010) were significant risk factors for OS. Performance status (p=0.022) was a significant risk factor for TRM. Eight patients with persistent or progressive disease received donor lymphocyte infusion, and two of them achieved complete remission. In conclusion, despite high TRM, allo-SCT is a viable option for patients with NHL who underwent progression after HDC with auto-SCT | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Springer International | - |
dc.relation.isPartOf | ANNALS OF HEMATOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adolescent | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Disease Progression* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Korea | - |
dc.subject.MESH | Lymphoma, Non-Hodgkin/physiopathology* | - |
dc.subject.MESH | Lymphoma, Non-Hodgkin/prevention & control* | - |
dc.subject.MESH | Lymphoma, Non-Hodgkin/therapy* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Recurrence | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Stem Cell Transplantation* | - |
dc.subject.MESH | Survival Rate | - |
dc.subject.MESH | Transplantation Conditioning | - |
dc.subject.MESH | Transplantation, Homologous*/adverse effects | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Young Adult | - |
dc.title | Allogeneic stem cell transplantation in patients with non-Hodgkin lymphoma who experienced relapse or progression after autologous stem cell transplantation. | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Ji-Won Kim | - |
dc.contributor.googleauthor | Byung-Su Kim | - |
dc.contributor.googleauthor | Soo-Mee Bang | - |
dc.contributor.googleauthor | Inho Kim | - |
dc.contributor.googleauthor | Dong Hwan Kim | - |
dc.contributor.googleauthor | Won Seog Kim | - |
dc.contributor.googleauthor | Deok-Hwan Yang | - |
dc.contributor.googleauthor | Je-Jung Lee | - |
dc.contributor.googleauthor | Je-Hwan Lee | - |
dc.contributor.googleauthor | Jin Seok Kim | - |
dc.contributor.googleauthor | Sang-Kyun Sohn | - |
dc.contributor.googleauthor | Ho-Young Yhim | - |
dc.contributor.googleauthor | Jae-Yong Kwak | - |
dc.contributor.googleauthor | Sung-Soo Yoon | - |
dc.contributor.googleauthor | Jong Seok Lee | - |
dc.contributor.googleauthor | Seonyang Park | - |
dc.contributor.googleauthor | Byoung Kook Kim | - |
dc.identifier.doi | 10.1007/s00277-011-1227-y | - |
dc.contributor.localId | A01017 | - |
dc.relation.journalcode | J00161 | - |
dc.identifier.eissn | 1432-0584 | - |
dc.identifier.pmid | 21468694 | - |
dc.identifier.url | https://link.springer.com/article/10.1007%2Fs00277-011-1227-y | - |
dc.subject.keyword | Non-Hodgkin lymphoma | - |
dc.subject.keyword | Stem cell transplantation | - |
dc.subject.keyword | Donor lymphocyte infusion | - |
dc.subject.keyword | Performance status | - |
dc.subject.keyword | Albumin | - |
dc.contributor.alternativeName | Kim, Jin Seok | - |
dc.contributor.affiliatedAuthor | 김진석 | - |
dc.citation.volume | 90 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 1409 | - |
dc.citation.endPage | 1418 | - |
dc.identifier.bibliographicCitation | ANNALS OF HEMATOLOGY, Vol.90(12) : 1409-1418, 2011 | - |
dc.identifier.rimsid | 60541 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.